tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

GLUE Stock Latest News

Monte Rosa Therapeutics announces FDA clearance of IND application for MRT-8102
The FlyMonte Rosa Therapeutics announces FDA clearance of IND application for MRT-8102
27d ago
GLUE
Buy Rating for Monte Rosa Therapeutics: Promising Pipeline and Strategic Partnerships Drive Positive Outlook
PremiumRatings
Buy Rating for Monte Rosa Therapeutics: Promising Pipeline and Strategic Partnerships Drive Positive Outlook
2M ago
GLUE
Monte Rosa Therapeutics Reports Strong Q1 2025 Earnings
PremiumCompany Announcements
Monte Rosa Therapeutics Reports Strong Q1 2025 Earnings
2M ago
GLUE
Monte Rosa Therapeutics: Promising Developments and Financial Stability Support Buy Rating
PremiumRatings
Monte Rosa Therapeutics: Promising Developments and Financial Stability Support Buy Rating
2M ago
GLUE
Monte Rosa Therapeutics Reports Strong Q1 2025 Results
PremiumCompany Announcements
Monte Rosa Therapeutics Reports Strong Q1 2025 Results
2M ago
8K
GLUE
Monte Rosa Therapeutics reports Q1 revenue $84.929M vs $1.064M last year
PremiumThe FlyMonte Rosa Therapeutics reports Q1 revenue $84.929M vs $1.064M last year
2M ago
GLUE
Promising Developments in Cancer Treatment: Monte Rosa Therapeutics’ MRT-51443 Gains Buy Rating
Premium
Ratings
Promising Developments in Cancer Treatment: Monte Rosa Therapeutics’ MRT-51443 Gains Buy Rating
2M ago
GLUE
Monte Rosa Therapeutics presents preclinical data at AACR on MRT-51443
Premium
The Fly
Monte Rosa Therapeutics presents preclinical data at AACR on MRT-51443
2M ago
GLUE
Monte Rosa Therapeutics Earnings Call Highlights Progress and Strategic Shifts
PremiumCompany Announcements
Monte Rosa Therapeutics Earnings Call Highlights Progress and Strategic Shifts
4M ago
GLUE
Monte Rosa Therapeutics price target raised to $17 from $15 at Wedbush
PremiumThe Fly
Monte Rosa Therapeutics price target raised to $17 from $15 at Wedbush
4M ago
GLUE
Promising Clinical Developments and Strategic Partnerships Drive Buy Rating for Monte Rosa Therapeutics
PremiumRatings
Promising Clinical Developments and Strategic Partnerships Drive Buy Rating for Monte Rosa Therapeutics
4M ago
GLUE
Monte Rosa Therapeutics price target lowered to $10 from $11 at Wells Fargo
PremiumThe Fly
Monte Rosa Therapeutics price target lowered to $10 from $11 at Wells Fargo
4M ago
GLUE
Monte Rosa Therapeutics Reports Strong Q4 2024 Results
PremiumCompany AnnouncementsMonte Rosa Therapeutics Reports Strong Q4 2024 Results
4M ago
GLUE
Monte Rosa Therapeutics files $400M mixed securities shelf
Premium
The Fly
Monte Rosa Therapeutics files $400M mixed securities shelf
4M ago
GLUE
Monte Rosa Therapeutics Reports Q4 2024 Financial Results
Premium
Company Announcements
Monte Rosa Therapeutics Reports Q4 2024 Financial Results
4M ago
8K
GLUE
Monte Rosa Therapeutics announces anticipated upcoming milestones
PremiumThe Fly
Monte Rosa Therapeutics announces anticipated upcoming milestones
4M ago
GLUE
Monte Rosa Therapeutics sees cash runway into 2028
PremiumThe Fly
Monte Rosa Therapeutics sees cash runway into 2028
4M ago
GLUE
Monte Rosa Therapeutics reports Q4 revenue $60.6M, consensus $51.9M
PremiumThe Fly
Monte Rosa Therapeutics reports Q4 revenue $60.6M, consensus $51.9M
4M ago
GLUE
Monte Rosa Therapeutics announces results from MRT-6160, MRT-2359 programs
PremiumThe Fly
Monte Rosa Therapeutics announces results from MRT-6160, MRT-2359 programs
4M ago
GLUE
Monte Rosa Therapeutics, Inc. (GLUE) Q4 Earnings Cheat Sheet
PremiumPre-EarningsMonte Rosa Therapeutics, Inc. (GLUE) Q4 Earnings Cheat Sheet
4M ago
GLUE
Monte Rosa Therapeutics initiated with an Outperform at LifeSci Capital
Premium
The Fly
Monte Rosa Therapeutics initiated with an Outperform at LifeSci Capital
4M ago
GLUE
Monte Rosa Therapeutics Outlines 2025 Milestones and Financial Strength
Premium
Company Announcements
Monte Rosa Therapeutics Outlines 2025 Milestones and Financial Strength
6M ago
8K
GLUE

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >